- Home
- BEATW vs UBXG Comparison
BEATW vs UBXG Comparison
Compare BEATW & UBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEATW
- UBXG
- Stock Information
- Founded
- BEATW 2015
- UBXG 2018
- Country
- BEATW United States
- UBXG China
- Employees
- BEATW 20
- UBXG N/A
- Industry
- BEATW Retail: Computer Software & Peripheral Equipment
- UBXG
- Sector
- BEATW Technology
- UBXG
- Exchange
- BEATW Nasdaq
- UBXG Nasdaq
- Market Cap
- BEATW N/A
- UBXG N/A
- IPO Year
- BEATW N/A
- UBXG 2024
- Fundamental
- Price
- BEATW $0.51
- UBXG $3.76
- Analyst Decision
- BEATW
- UBXG
- Analyst Count
- BEATW 0
- UBXG 0
- Target Price
- BEATW N/A
- UBXG N/A
- AVG Volume (30 Days)
- BEATW 4.7K
- UBXG 27.8K
- Earning Date
- BEATW 03-14-2025
- UBXG 12-31-2024
- Dividend Yield
- BEATW N/A
- UBXG N/A
- EPS Growth
- BEATW N/A
- UBXG N/A
- EPS
- BEATW N/A
- UBXG N/A
- Revenue
- BEATW N/A
- UBXG $51,600,106.00
- Revenue This Year
- BEATW N/A
- UBXG N/A
- Revenue Next Year
- BEATW N/A
- UBXG N/A
- P/E Ratio
- BEATW N/A
- UBXG N/A
- Revenue Growth
- BEATW N/A
- UBXG N/A
- 52 Week Low
- BEATW $0.50
- UBXG $0.26
- 52 Week High
- BEATW $0.62
- UBXG $35.44
- Technical
- Relative Strength Index (RSI)
- BEATW N/A
- UBXG N/A
- Support Level
- BEATW N/A
- UBXG N/A
- Resistance Level
- BEATW N/A
- UBXG N/A
- Average True Range (ATR)
- BEATW 0.00
- UBXG 0.00
- MACD
- BEATW 0.00
- UBXG 0.00
- Stochastic Oscillator
- BEATW 0.00
- UBXG 0.00
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.